<DOC>
	<DOCNO>NCT00302471</DOCNO>
	<brief_summary>This two part study evaluate safety tolerability MK0429 addition assess 's pharmacokinetic profile pharmacodynamic response .</brief_summary>
	<brief_title>MK0429 Study Prostate Cancer Patients With Metastatic Bone Disease ( 0429-011 )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Eligible patient must : Prostate cancer Bone metastases without symptom Lack response hormone therapy evidence rise PSA clinical progression Prostate cancerrelated bone pain Previously receive bisphosphonate therapy ( e.g . zoledronate ) Received investigational treatment within last 30 day</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>